多囊卵巢
胰岛素抵抗
高雄激素血症
医学
内分泌学
内科学
高胰岛素血症
不育
无排卵
减肥
超重
2型糖尿病
肥胖
糖尿病
怀孕
生物
遗传学
作者
Georgios S. Papaetis,Angelos Kyriacou
出处
期刊:Advances in Clinical and Experimental Medicine
[Wroclaw Medical University]
日期:2022-08-11
卷期号:31 (11): 1265-1274
被引量:11
摘要
Polycystic ovary syndrome (PCOS) is a disorder that involves several organ systems and cellular pathways. It is strongly influenced by environmental and epigenetic factors. The principal goal of all therapeutic approaches to individuals with reproductive abnormalities is the treatment of subfertility or the regulation of menstruation when pregnancy is not desired. Obesity is closely related to insulin resistance (IR) and subsequent hyperinsulinemia, which aggravate hyperandrogenism and impair early follicle development. Weight loss is of vital importance for overweight/obese individuals with anovulatory infertility. The GLP-1R agonists have achieved remarkable weight reduction and abdominal fat loss in patients with type 2 diabetes (T2D), as well as in overweight/obese individuals and individuals with prediabetes. They have also been shown to promote lower fasting insulin levels and insulin resistance markers. These beneficial effects have been suggested to be particularly helpful in women with PCOS, while their possible role in the hypothalamic-pituitary-gonadal axis is under intense research. This review analyzes the current evidence for GLP-1R agonists, focusing on their effects on ovarian morphology, menstrual dysfunction and fertility outcomes. It also discusses their future role in achieving targeted therapeutic approaches.
科研通智能强力驱动
Strongly Powered by AbleSci AI